ArticleJournal of applied genetics2026
Alpha-methylacyl-CoA racemase (AMACR) deficiency: report on novel patient and literature review.
Article in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-methylacyl-CoA racemase (AMACR) deficiency is an autosomal recessive disorder of peroxisomal β-oxidation of branched-chain fatty acids and C27-bile acids. Since its first report in 2000, several children were diagnosed via molecular analyses, mostly due to elevated liver enzymes. Here we present an early-onset form of AMACR deficiency in clinically asymptomatic child who was diagnosed upon incidental findings of elevated liver enzymes and glucosuria. This case expands the phenotypic (biochemical) spectrum of AMACR deficiency. The manuscript was enriched by the literature review on patients with AMACR deficiency diagnosed in childhood. We recommend to perform serum/plasma peroxisomal metabolites, including VLCFA, bile acids intermediates and phitanic and pristanic acid, in every children with persistently elevated liver enzymes, especially with coagulopathy and with or without cholestatic jaundice.
Indexed as
Identifiers
41766008What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.